SCHEMBL2274567

SCHEMBL2274567

CC1(C)COB(c2ccccc2)OC1

nearest known ligand 0.42

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
LPL P06858 3/20 0.42
LIPG Q9Y5X9 3/20 0.42
SNCA P37840 1/20 0.39
P4HB P07237 1/20 0.31
SOAT1 P35610 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4264297 0.89 SNCA (0.44) LPLLIPGSNCA
SCHEMBL26648626 0.88 LIPG (0.59) LPLLIPGSNCAP4HBSOAT1
SCHEMBL16426133 0.85 SNCA (0.38) LPLLIPGSNCA
SCHEMBL3788621 0.84 APP (0.40) LPLLIPGSNCA
SCHEMBL5528199 0.83 SNCA (0.40) LPLLIPGSNCA
SCHEMBL4257326 0.83 SNCA (0.48) LPLLIPGSNCA
SCHEMBL16626102 0.81 LPL (0.37) LPLLIPGSNCA
SCHEMBL12370809 0.81 SNCA (0.41) LPLLIPGSNCA
SCHEMBL2538252 0.79 SNCA (0.38) SNCA
SCHEMBL3186952 0.79 SNCA (0.40) LPLLIPGSNCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12633548-B2 Eliminating voltage delay and stabilizing impedance by electrolyte additives in alkali metal electrochemical cells LITRONIK BATTERIETECHNOLOGIE GMBH (DE) 2026-05-19 US claimed
US-20220263102-A1 ELIMINATING VOLTAGE DELAY AND STABILIZING IMPEDANCE BY ELECTROLYTE ADDITIVES IN ALKALI METAL ELECTROCHEMICAL CELLS LITRONIK BATTERIETECHNOLOGIE GMBH (DE) 2022-08-18 US claimed
EP-3997748-A1 ELIMINATION OF VOLTAGE DELAY AND STABILIZATION OF IMPEDANCE BY ELECTROLYTE ADDITIVES IN ALKALI METAL ELECTROCHEMICAL CELLS LITRONIK Batterietechnologie GmbH (DE) 2022-05-18 EP claimed
US-12633548-B2 Eliminating voltage delay and stabilizing impedance by electrolyte additives in alkali metal electrochemical cells LITRONIK BATTERIETECHNOLOGIE GMBH (DE) 2026-05-19 US disclosed
US-12012639-B2 Processes for isolation and recovery of C5 sugars UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2024-06-18 US disclosed
US-20240110914-A1 Devices and Methods for Detection of Viruses from Exhaled Breath NATIONAL SCIENCE FOUNDATION 2024-04-04 US disclosed
US-11803122-B2 Chemical amplification-type photosensitive composition, photosensitive dry film, production method of patterned resist layer, production method of plated molded article, compound, and production method of compound TOKYO OHKA KOGYO CO., LTD. (JP) 2023-10-31 US disclosed
US-11803122-B2 Chemical amplification-type photosensitive composition, photosensitive dry film, production method of patterned resist layer, production method of plated molded article, compound, and production method of compound TOKYO OHKA KOGYO CO., LTD. (JP) 2023-10-31 US disclosed
US-11754926-B2 Method of forming resist pattern, resist composition and method of producing the same TOKYO OHKA KOGYO CO., LTD. (JP) 2023-09-12 US disclosed
US-11754926-B2 Method of forming resist pattern, resist composition and method of producing the same TOKYO OHKA KOGYO CO., LTD. (JP) 2023-09-12 US disclosed
WO-2023167325-A1 IMMOBILIZED PALLADIUM CATALYST AND METHOD FOR PRODUCING SAME, AND APPLICATION OF THIS CATALYST TO COUPLING REACTION 国立研究開発法人理化学研究所 2023-09-07 WO disclosed
US-20090054436-A1 MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2009-02-26 US disclosed
US-20090054436-A1 MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2009-02-26 US disclosed
US-7459562-B2 Monocyclic heterocycles as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-12-02 US disclosed
US-7459562-B2 Monocyclic heterocycles as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-12-02 US disclosed
EP-1584621-B1 A process for the preparation of tolterodine and intermediates thereof DIPHARMA FRANCIS SRL (IT) 2007-06-13 EP disclosed
US-7179940-B2 (Aryl)(amino) borane compounds, method for preparing same CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2007-02-20 US disclosed
US-7119212-B2 Process for the preparation of tolterodine and intermediates thereof DIPHARMA S.P.A. (IT) 2006-10-10 US disclosed
EP-1584621-A1 A process for the preparation of tolterodine and intermediates thereof Dipharma S.p.A. (IT) 2005-10-12 EP disclosed
US-20050222437-A1 Process for the preparation of tolterodine and intermediates thereof DIPHARMA S.P.A. (IT) 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222437-A1 Process for the preparation of tolterodine and intermediates thereof CYP2B6, UGT1A6, CYP2D6 LPL 4153/4885LIPG 4796/4885SNCA 1445/4885
US-20090054436-A1 MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS CDK2, MAP3K19, CDK1 LPL 4794/4885LIPG 4176/4885SNCA 4876/4885
US-12633548-B2 Eliminating voltage delay and stabilizing impedance by electrolyte additives in alkali metal electrochemical cells KCNN1, HCN4, KCNN2 LPL 4624/4885LIPG 4122/4885SNCA 2633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.